Richard Fuller, M.D., Ph.D.
Richard Fuller, M.D., Ph.D. provides advisory services in area of clinical development and strategy to life science companies. Dr. Fuller was a Research Fellow at Imperial College London. He has published widely in medical and scientific literature. Following his academic career, he held executive roles in clinical research at Glaxo Smith Kline plc. Dr. Fuller then was Director of Science Funding for the Wellcome Trust, a not-for-profit research donor organization. Subsequently he was CMO of Aerovance Inc. Following Aerovance, he was CEO of Oriel Therapeutics, Inc. which was acquired by Novartis AG. Dr. Fuller is a member of The General Medical Council UK, Royal College of Physicians of London, and The American Thoracic Society.